Filing Flows › TG Therapeutics (TGTX) › License revenue
TG Therapeutics (TGTX) License revenue by quarter
TG Therapeutics' License revenue was $4.5M in Q2 2026 (second quarter 2026), +26% from Q1 2026. Over the last 6 quarters it ranged from $838K (Q4 2024) to $4.5M (Q2 2026).
| Quarter | License revenue | Q/Q | Y/Y |
|---|---|---|---|
| Q2 2026 | $4.5M | +26% | +97% |
| Q1 2026 | $3.6M | +4% | — |
| Q4 2025 | $3.5M | +45% | +313% |
| Q3 2025 | $2.4M | +4% | — |
| Q2 2025 | $2.3M | +175% | — |
| Q4 2024 | $838K | — | — |
Q2 2026 at a glance
TG Therapeutics, Q2 2026: revenue $240M (+70% year over year), operating margin 9.0%, net earnings $7.8M, operating cash flow $39.3M. The chart follows the revenue to costs, profit and cash.
Questions
What is TG Therapeutics' License revenue?
TG Therapeutics' License revenue was $4.5M in Q2 2026 (second quarter 2026), +26% from Q1 2026.
How has TG Therapeutics' License revenue changed?
Over the last 6 quarters it ranged from $838K (Q4 2024) to $4.5M (Q2 2026).